RATIONALE: Allergic Rhinitis (AR) is linked to early-life allergen sensitization. Patterns of sensitization may confer differential risk for AR. We assessed whether the risk of childhood AR differed depending upon allergen sensitization profiles at age 2-3 years. METHODS: Allergen sensitization to seven inhalant and three food allergens were assessed by specific IgE at age 2-3 years among participants in the Detroit-area WHEALS birth cohort. Positive tests were defined by specific IgE> _0.35 IU/ml. Four previously identified sensitization patterns at age 2-3 were also examined: low/no sensitization (LS); highly multiplysensitized (HS); milk/egg dominated sensitization (MES) and peanut/ inhalant sensitization (PIS). Current AR was determined by physician evaluation during a study-related visit at age 10-12 years. Relative risks (RR) for AR were calculated for the sensitization frequency and pattern categories determined at age 2-3 years. RESULTS: Compared to 185 non-sensitized children, the risk of AR was not statistically significantly higher for the 69 children with one positive test (RR51.19, 95% CI50.94,1.50; p50.16) but higher for the 91 children with > _2 positive tests (RR51.46, 95% CI51.21,1.75; p<0.001). Compared to 259 LS children, the risk of AR was greater (RR51.68,95% CI51.39, 2.04; p<0.001) for the 13 HS children, the 54 MES children (RR51.25, 95% CI51.01, 1.55; p50.039), and the 19 PIS children (RR51.34, 95% CI51.01, 1.80; p50.046). CONCLUSIONS: Children with multiple (> _2) positive IgE tests at age 2-3 years were at higher risk for AR in the preteen years. Multi-sensitization as opposed to mono-sensitization may be a marker for allergic predisposition.
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Enhanced chemosensory sensitivity in idiopathic rhinitis patients and its reversal by nasal capsaicin treatment.
Laura H. Van Gerven, MD, PhD; KULeuven, Leuven, Belgium.
INTRODUCTION AND RATIONALE:
We recently showed that the therapeutic action of capsaicin treatment in idiopathic rhinitis (IR) is based on the ablation of the TRPV1-Substance P nociceptive signaling pathway (Van Gerven et al., JACI 2013) . However, the functional consequences of capsaicin treatment on nasal nerve activation remain unknown. METHODS: A double-blinded placebo-controlled trial, involving 33 IR patients and 12 healthy controls (HC). Nasal mucosal potentials (NMP) were evoked by exposing the nasal mucosa of IR patients and HC to an aerosol with different TRP-agonists. Low concentrations of 3 irritants (cinnamaldehyde, allyl isothiocyanate (mustard oil, MO) and capsaicin) that activate TRPA1 and/or TRPV1 were applied. The threshold for each irritant was determined for each individual as the dose at which a clear change from baseline in NMP was recorded. RESULTS: The threshold for MO was 5 mM in 9 %, 10 mM in 18% and 20 mM in 73% of HC, whereas for IR patients, 31.5% responded by an NMPdecrease at 5 mM, 37% on 10 mM and 31.5% on 20 mM. The MOthreshold was overall significantly lower for IR patients compared to HC (P 5 0.0423). Remarkably, no changes in NMP measurements could be documented after cinnamaldehyde. Capsaicin exposure induced cough that hampered NMP recording. CONCLUSIONS: The lower chemical threshold to react to MO in IR patients compared to HC confirmed the specific role of these nociceptors in the pathophysiology of IR, which in turn, may help to design more specific and effective therapies. We report safety data of 300IR 5-grass tablet* for patient subgroups with/without controlled asthma in a post-marketing study of children (aged 5-9 years) with grass pollen-induced allergic rhinitis/ rhinoconjunctivitis (GP-AR). METHODS: This study (NCT02295969) included immunotherapy-na€ ıve children with GP-AR prescribed daily 5-grass tablet in accordance with the product information which contraindicates use in patients with severe, unstable, or uncontrolled asthma. Patients were followed-up over the first 30 treatment days. Adverse drug reactions (ADRs) were described. RESULTS: Among 307 enrolled children (mean age: 7.1 years), 111 (36%) were asthmatic. As previously reported, 173/307 (56%) patients had ADRs, generally application-site reactions and two patients (1 CONCLUSIONS: This analysis represents the largest studied subpopulation (n>100) of asthmatic patients aged 5-9 years administered 5-grass tablet. Over one month of real-life treatment conditions, this subpopulation showed no meaningful differences in safety profile versus non-asthmatic patients. This is consistent with a smaller asthmatic pediatric subpopulation (n557) studied during clinical development of the product. *US indication is for patients aged 10-65
